Experts call for regulation of kratom and potent 7-OH products, debate over specific rules

Kratom leaf products have been sold in the United States for many years without formal regulatory oversight. Users often turn to them for chronic pain, anxiety, or to ease opioid withdrawal, despite known risks of physical dependence.

A newer, semi‑synthetic derivative called 7‑hydroxymitragynine, or 7‑OH, is appearing in more concentrated forms. Clinicians and recovery advocates warn that these high‑potency products could be even more addictive than traditional kratom, although scientific data are limited.

Most experts agree that some form of regulation is needed, but they differ on the details. The Drug Enforcement Administration recently suggested a temporary Schedule I classification for 7‑OH products that exceed a certain potency threshold, while allowing lower‑strength kratom to remain unregulated.

The discussion highlights a broader tension between ensuring public safety and preserving access to substances that some users find beneficial. A final regulatory framework has yet to be decided.